Skip to Content

WPI 844 (Glipizide Extended Release 5 mg)

Pill with imprint WPI 844 is Orange, Round and has been identified as Glipizide extended release 5 mg. It is supplied by Watson Laboratories, Inc..

Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 5 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for WPI 844

Glipizide extended release 5 mg WPI 844
Glipizide extended release 5 mg WPI 844  Front
Glipizide extended release 5 mg WPI 844  Back
Glipizide extended release 5 mg WPI 844

Glipizide extended release

WPI 844
5 mg
6.00 mm
Prescription only
Drug Class:
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Watson Laboratories, Inc.
Inactive Ingredients:
acetyltributyl citrate
hydroxyethyl cellulose (2000 mpa.s at 1%)
hydroxypropyl cellulose (type h)
lactose monohydrate
magnesium stearate
methacrylic acid - methyl methacrylate copolymer (1:1)
polyethylene glycol
FD&C Yellow No. 6
isopropyl alcohol
ferrosoferric oxide
butyl alcohol
propylene glycol
Note: Inactive ingredients may vary.

Other Labelers / Repackagers:

NDC CodeLabeler / Repackager
68084-0111 Amerisource Health Services
10370-0190 Anchen Pharmaceuticals, Inc.
54569-5547 A-S Medication Solutions, LLC (repackager)
54868-5210 Physicians Total Care Inc. (repackager)

Get help with Imprint Code FAQs.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2018, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.